Compare Bristol-Myers Squibb Co (BMY) vs Opendoor Technologies Inc (OPEN) Price & Performance

Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.

BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.

Opendoor (OPEN) trades at $4.485, down 5.86% today, reflecting ongoing volatility amid a challenging housing market. The stock shows a bearish technical trend with support near $4 and resistance at $5. Fundamentally, the company reported a net loss of $1.30 billion on $4.37 billion revenue in 2025, with a negative net margin of 35.25%. Recent news highlights CEO leadership and a shift toward AI, including the closure of India operations affecting 250 employees (Reuters, 2026-06-11).

The outlook remains cautious due to persistent losses and high debt, though the low P/S ratio of 0.94 offers some valuation appeal. Risks include execution of the new business model, interest rate sensitivity, and competitive pressure. Analyst sentiment is mixed with 65.39% hold ratings, indicating wait-and-see approach until sustained profitability emerges.